On April 19, 2018, KEI filed a lawsuit against the NIH license of CD30 CAR T patents to Gilead. On April 11, 2019, the lawsuit was dismissed on the grounds that KEI lacked standing. KEI blogs January 5, 2018. 2018: Briefing note… Continue Reading →
On 9 July 2018, Indonesia delivered this opening statement on behalf of the Asia & the Pacific Group at the 28th session of the WIPO Standing Committee on the Law of Patents (SCP). Opening Statement by the Republic of Indonesia… Continue Reading →
On July 2, 2018, Knowledge Ecology International (KEI) filed comments to the National Institutes of Health (NIH) regarding the prospective grant of an exclusive license to the University of Liverpool, located in the U.K. The inventions described in the Federal… Continue Reading →
Update: the NIH has rejected our request for expedited processing of the FOIA, on the grounds that KEI did not demonstrate “that there exists an urgency to inform the public” about the costs of the NIH CAR T or mesothelin… Continue Reading →
On June 25, 2018, plaintiff KEI filed a memorandum in opposition to a motion to dismiss filed by defendants NIH et al. The opposition cites the declaration of KEI Director James Love. The original KEI complaint is here: https://www.keionline.org/27669 The… Continue Reading →
Today Knowledge Ecology International (KEI), the Union for Affordable Cancer Treatment (UACT), Health GAP, Social Security Works (SSW), People of Faith for Access to Medicines (PFAM), Universities Allied for Essential Medicines (UAEM) and Dean Baker filed comments to the National… Continue Reading →
The NIH has filed a motion to dismiss in our lawsuit over the NIH license of CAR T patents to Gilead. See original KEI complaint here: https://www.keionline.org/27669. As expected, the NIH is challenging KEI’s standing. KEI has 15 days to… Continue Reading →
(Update: The NIH provided a response to our comments on July 16, 2018) Below are comments sent by KEI, UACT and HealthGap, regarding a proposed exclusive license to Morphiex Biotherapeutics, an entity for which little is known. The license concerns… Continue Reading →
The below are comments were filed by KEI and HealthGap on May 22, 2018, regarding a proposed NIH exclusive license on patents for the treatment and diagnosis of Crohn’s Disease, Ulcerative Colitis, Asthma, Psoriasis and Biliary Cirrhosis to Precision IBD… Continue Reading →
At the 71st World Health Assembly, KEI will deliver the following intervention regarding the Draft thirteenth general programme of work, 2019–2023. Strategic priority matters 11.1 Draft thirteenth general programme of work, 2019–2023 KEI endorses the WHO’s unwavering commitment to universal… Continue Reading →